Sugi Predict

Sugi Predict / Targets / CCR10

CCR10

C-C chemokine receptor type 10 · P46092 · CCR10 on Sugi Atlas →

1,986 patent compounds predicted against CCR10, 1,298 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1032242 SCHEMBL1032242 1.00 20/20
SCHEMBL1034287 SCHEMBL1034287 1.00 20/20
SCHEMBL1035118 SCHEMBL1035118 1.00 20/20
SCHEMBL1035295 SCHEMBL1035295 1.00 20/20
SCHEMBL1035303 SCHEMBL1035303 1.00 20/20
SCHEMBL1035594 SCHEMBL1035594 1.00 20/20
SCHEMBL1036426 SCHEMBL1036426 1.00 20/20
SCHEMBL1036626 SCHEMBL1036626 1.00 20/20
SCHEMBL1036738 SCHEMBL1036738 1.00 20/20
SCHEMBL1036899 SCHEMBL1036899 1.00 20/20
SCHEMBL1037145 SCHEMBL1037145 1.00 20/20
SCHEMBL1037334 SCHEMBL1037334 1.00 20/20
SCHEMBL1073855 SCHEMBL1073855 1.00 20/20
SCHEMBL1074886 SCHEMBL1074886 1.00 20/20
SCHEMBL1075128 SCHEMBL1075128 1.00 20/20
SCHEMBL1075991 SCHEMBL1075991 1.00 20/20
SCHEMBL1076696 SCHEMBL1076696 1.00 20/20
SCHEMBL1076908 SCHEMBL1076908 1.00 20/20
SCHEMBL1077312 SCHEMBL1077312 1.00 20/20
SCHEMBL1083435 SCHEMBL1083435 1.00 20/20

Clinical trials — most relevant to CCR10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Polyvalent Immunoglobulin in COVID-19 Related ARds PHASE3COMPLETED
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia PHASE3SUSPENDED
Tocilizumab Treatment in Patients With COVID-19 PHASE2ACTIVE_NOT_RECRUITING
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver PHASE2COMPLETED
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) PHASE1RECRUITING
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL PHASE1ACTIVE_NOT_RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation PHASE1RECRUITING
U69-CART-Cells For R/R T-ALL PHASE1RECRUITING
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021 nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19 nanCOMPLETED
Significance of MAIT Cells in Inflammatory Bowel Disease nanUNKNOWN
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA) nanUNKNOWN
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy nanCOMPLETED
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure nanUNKNOWN
Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis. nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCR10 binder may also engage these)

ProteinNameSimilarity
Q9JL21 — 1.000 Q9JL21 →
Q924U0 — 0.989 Q924U0 →
Q9JJL9 — 0.988 Q9JJL9 →
LTB4R2 Leukotriene B4 receptor 2 0.986 landscape →
O00155 — 0.984 O00155 →
P0C5I1 — 0.978 P0C5I1 →
F2RL3 Proteinase-activated receptor 4 0.975 landscape →
LTB4R Leukotriene B4 receptor 1 0.971 landscape →
A0A6I8PUB9 — 0.969 A0A6I8PUB9 →
Q76JV1 — 0.966 Q76JV1 →
Q5KSK8 — 0.966 Q5KSK8 →
O88634 — 0.966 O88634 →
Q3T181 — 0.964 Q3T181 →
Q8HYC3 — 0.964 Q8HYC3 →
Q920E0 — 0.962 Q920E0 →
RXFP4 Relaxin-3 receptor 2 0.961 landscape →
GALR3 Galanin receptor type 3 0.961 landscape →
C5AR2 C5a anaphylatoxin chemotactic receptor 2 0.959 landscape →
Q9BDQ5 — 0.958 Q9BDQ5 →
Q76JU9 — 0.958 Q76JU9 →
FFAR1 Free fatty acid receptor 1 0.957 landscape →
UTS2R Urotensin-2 receptor 0.957 landscape →
Q76JU8 — 0.956 Q76JU8 →
O88855 — 0.955 O88855 →
Q9R0Q2 — 0.954 Q9R0Q2 →
PTGDR2 Prostaglandin D2 receptor 2 0.952 landscape →
O88626 — 0.952 O88626 →
Q8K3T4 — 0.951 Q8K3T4 →
P2RY11 P2Y purinoceptor 11 0.950 landscape →
Q99678 — 0.950 Q99678 →